GRI Bio to Present at AGP's 2024 Healthcare Showcase

GRI Bio, Inc. (NASDAQ: GRI), a biotechnology company focused on pioneering treatments for inflammatory, fibrotic, and autoimmune diseases, has announced that its Chief Executive Officer, Marc Hertz, PhD, will be participating in a fireside chat at the Healthcare Company Showcase. This event, hosted by Alliance Global Partners, is scheduled for Tuesday, May 21, 2024, at 2:40 PM ET. Those interested can access a live webcast of the discussion via the Events page in the Investors section of GRI Bio's website.

GRI Bio is dedicated to transforming the treatment landscape for inflammatory, fibrotic, and autoimmune conditions. The company's therapeutic strategies revolve around modulating Natural Killer T (NKT) cells, which are crucial early regulators in the inflammatory process. By targeting NKT cell activity, GRI Bio aims to halt disease progression and reestablish immune system balance. NKT cells are unique in that they possess characteristics of both NK and T cells, making them a vital link between the body's innate and adaptive immune responses. In particular, invariant NKT (iNKT) cells are instrumental in driving the injury, inflammation, and fibrosis seen in various inflammatory and fibrotic diseases.

The company's flagship program, GRI-0621, is an oral therapeutic designed to inhibit iNKT cell activity. This drug is being developed to treat idiopathic pulmonary fibrosis, a severe condition with limited treatment options. Beyond GRI-0621, GRI Bio is also working on a range of type 2 NKT agonists aimed at treating systemic lupus erythematosus. With a proprietary library exceeding 500 compounds, GRI Bio is well-positioned to expand its pipeline and explore new therapeutic avenues.